Show simple item record

dc.contributor.authorPrat, Aen_US
dc.contributor.authorLluch, Aen_US
dc.contributor.authorTurnbull, AKen_US
dc.contributor.authorDunbier, AKen_US
dc.contributor.authorCalvo, Len_US
dc.contributor.authorAlbanell, Jen_US
dc.contributor.authorde la Haba-Rodríguez, Jen_US
dc.contributor.authorArcusa, Aen_US
dc.contributor.authorChacón, JIen_US
dc.contributor.authorSánchez-Rovira, Pen_US
dc.contributor.authorPlazaola, Aen_US
dc.contributor.authorMuñoz, Men_US
dc.contributor.authorParé, Len_US
dc.contributor.authorParker, JSen_US
dc.contributor.authorRibelles, Nen_US
dc.contributor.authorJimenez, Ben_US
dc.contributor.authorBin Aiderus, AAen_US
dc.contributor.authorCaballero, Ren_US
dc.contributor.authorAdamo, Ben_US
dc.contributor.authorDowsett, Men_US
dc.contributor.authorCarrasco, Een_US
dc.contributor.authorMartín, Men_US
dc.contributor.authorDixon, JMen_US
dc.contributor.authorPerou, CMen_US
dc.contributor.authorAlba, Een_US
dc.date.accessioned2017-07-19T15:34:40Z
dc.date.issued2017-06en_US
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2017, 23 (12), pp. 3035 - 3044en_US
dc.identifier.issn1078-0432en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/724
dc.identifier.eissn1557-3265en_US
dc.identifier.doi10.1158/1078-0432.ccr-16-2092en_US
dc.description.abstract<b>Purpose:</b> Hormone receptor-positive (HR<sup>+</sup>) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified.<b>Experimental Design:</b> Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR<sup>+</sup>/HER2<sup>-</sup> disease randomly assigned to neoadjuvant multiagent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based chemoendocrine score (CES). CES's predictive ability was evaluated in 4 independent neoadjuvant data sets (<i>n</i> = 675) and 4 adjuvant data sets (<i>n</i> = 1,505). The association of CES, intrinsic biology, and PAM50 risk of relapse (ROR) was explored across 6,007 tumors.<b>Results:</b> Most genes associated with endocrine sensitivity were also found associated with chemotherapy resistance. In the chemotherapy test/validation data sets, CES was independently associated with pathologic complete response (pCR), even after adjusting for intrinsic subtype. pCR rates of the CES endocrine-sensitive (CES-E), uncertain (CES-U), and chemotherapy-sensitive (CES-C) groups in both data sets combined were 25%, 11%, and 2%, respectively. In the endocrine test/validation data sets, CES was independently associated with response. Compared with ROR, >90% of ROR-low and ROR-high tumors were identified as CES-E and CES-C, respectively; however, each CES group represented >25% of ROR-intermediate disease. In terms of survival outcome, CES-C was associated with poor relapse-free survival in patients with ROR-intermediate disease treated with either adjuvant endocrine therapy only or no adjuvant systemic therapy, but not in patients treated with (neo)adjuvant chemotherapy.<b>Conclusions:</b> CES is a genomic signature capable of estimating chemoendocrine sensitivity in HR<sup>+</sup> breast cancer beyond intrinsic subtype and risk of relapse. <i>Clin Cancer Res; 23(12); 3035-44. ©2016 AACR</i>.en_US
dc.formatPrint-Electronicen_US
dc.format.extent3035 - 3044en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectBreast Neoplasmsen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectRecurrenceen_US
dc.subjectReceptor, erbB-2en_US
dc.subjectNeoplasm Proteinsen_US
dc.subjectReceptors, Estrogenen_US
dc.subjectReceptors, Progesteroneen_US
dc.subjectAntineoplastic Agents, Hormonalen_US
dc.subjectPrognosisen_US
dc.subjectNeoadjuvant Therapyen_US
dc.subjectGene Expression Regulation, Neoplasticen_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.titleA PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-11-07en_US
rioxxterms.versionofrecord10.1158/1078-0432.ccr-16-2092en_US
rioxxterms.licenseref.startdate2017-06en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Researchen_US
pubs.issue12en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume23en_US
pubs.embargo.termsNot knownen_US
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record